What's happened
Cambridge and ICR researchers show NICE criteria miss up to 95% of women under 50 who will develop breast cancer within 10 years. A new model called Boadicea identifies eight times as many high-risk women, prompting calls for review and investment to implement multifactorial risk assessment across the NHS.
What's behind the headline?
Insightful analysis
- NICE criteria are simpler to apply but miss a large share of high-risk under-50s; Boadicea could reclassify roughly a quarter as above-average risk, including about one-third of those who will develop cancer within 10 years.
- The trade-off is resource strain: broader referral networks require more screening capacity and genetic testing is costly.
- A balance is needed between implementation practicality and potential benefits of accurate risk classification.
- The public health implication is clear: expanding multifactorial risk assessment could improve early detection, but it must be paired with investment in family-history services across the NHS.
How we got here
The NICE criteria used in England for referring women under 50 for breast-cancer risk assessment rely largely on family history. Cambridge University and the Institute of Cancer Research developed Boadicea, a multifactorial risk model that includes lifestyle, reproductive history and genetics. The study, published in the British Journal of Cancer, compares NICE with Boadicea and estimates referrals and eventual cancer development under both approaches. This work follows broad concern that early identification could improve outcomes but raises questions about resources and equitable access.
Our analysis
The Guardian reports that NICE has welcomed the findings but says current evidence does not warrant changing guidelines; the BBC and Independent mirror this stance while emphasising the potential of multifactorial models like Boadicea. All note that three-quarters of under-50 women who develop cancer have no family history, which underpins the call for review. Direct quotes in the sources include University of Cambridge researchers Juliet Usher-Smith and Institute of Cancer Research's Montserrat Garcia-Closas, alongside statements from Breast Cancer Now and Cancer Research UK.
Go deeper
- What would a full rollout of Boadicea require financially and logistically?
- How might patient anxiety be managed if referrals increase?
- What timelines are realistic for NICE to reconsider family-history guidelines?
More on these topics
-
Cancer Research UK - Corporation
Cancer Research UK is a cancer research and awareness charity in the United Kingdom and Isle of Man, formed on 4 February 2002 by the merger of The Cancer Research Campaign and the Imperial Cancer Research Fund.
-
University of Cambridge - Collegiate university in Cambridge, England
The University of Cambridge is a collegiate research university in Cambridge, United Kingdom. Founded in 1209 and granted a royal charter by King Henry III in 1231, Cambridge is the second-oldest university in the English-speaking world and the world's fo
-
Institute of Cancer Research - Research institute in London, England
The Institute of Cancer Research (the ICR) is a public research institute and a member institution of the University of London in London, United Kingdom, specialising in oncology. It was founded in 1909 as a research department of the Royal Marsden Hospital and joined the University of London in 2003. It has been responsible for a number of breakthrough discoveries, including that the basic cause of cancer is damage to DNA. The ICR occupies sites in Chelsea, Central London and Sutton, southwest London. The ICR provides both taught postgraduate degree programmes and research degrees and currently has around 340 students. Together with the Royal Marsden Hospital the ICR forms the largest comprehensive cancer centre in Europe, and was ranked second amongst all British higher education institutions in the Times Higher Education's assessment of the 2021 Research Excellence Framework. In clinical medicine, 97% and in biological sciences, 99% of the ICR's academic research was assessed to be world leading or internationally excellent (4* or 3*). The annual income of the institution for 2022–23 was £138.7 million of which £64.6 million was from research grants and contracts, with an expenditure...
-
United Kingdom - Country in Europe
The United Kingdom of Great Britain and Northern Ireland, commonly known as the United Kingdom or Britain, is a sovereign country located off the northwestern coast of the European mainland.
-
Breast Cancer Now - Charity in the UK
Breast Cancer Now is a charity in the United Kingdom which was formed in 2015 by the merger of Breast Cancer Campaign and Breakthrough Breast Cancer. It is the United Kingdom's largest breast cancer charity. Its declared "Action Plan" is "by 2050, everyon
-
British Journal of Cancer - Journal
The British Journal of Cancer (BJC) is a twice-monthly professional medical journal published by Springer Nature. The BJC provides a forum for clinicians and scientists to communicate original research findings that have relevance to understanding the etiology of cancer and to improving patient treatment and survival. Once accepted, papers are published in print and online. Full research papers are published under six broad headings: Clinical studies Translational therapeutics Molecular diagnostics Genetics and genomics Cellular and molecular biology Epidemiology
-
England - Country of the United Kingdom
England is a country that is part of the United Kingdom. It shares land borders with Wales to its west and Scotland to its north. The Irish Sea lies northwest of England and the Celtic Sea to the southwest. England is separated from continental Europe by